# Atezolizumab Immunotherapy in Patients With Advanced NSCLC

> **NCT03102242** · PHASE2 · COMPLETED · sponsor: **Alliance Foundation Trials, LLC.** · enrollment: 64 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03102242
- **Lead sponsor:** Alliance Foundation Trials, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-01
- **Primary completion:** 2020-06-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03102242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03102242, "Atezolizumab Immunotherapy in Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03102242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*